Gland Pharma posts 16% revenue growth in Q1 FY25
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Shivani Satish Wagh takes on the role of Joint Managing Director
Subscribe To Our Newsletter & Stay Updated